{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05039177\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["ERAS-007","encorafenib","cetuximab"],["ERAS-007","palbociclib"]],"indication":"metastatic colorectal cancer or pancreatic ductal adenocarcinoma","name":"HERKULES-3","nct_id":"NCT05039177","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=herkules-3-nct05039177. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HERKULES-3","arms":[{"description":"ERAS-007 will be orally administered in combination with encorafenib and cetuximab to study participants with BRAFm CRC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.","label":"Dose Escalation (Parts A1a, A2a, or A3a): ERAS-007 in combination with encorafenib and cetuximab","type":"EXPERIMENTAL"},{"description":"ERAS-007 will be orally administered in combination with palbociclib to study participants with KRASm or NRASm CRC and KRASm PDAC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.","label":"Dose Escalation (Parts B1a, B2a, B3a or B4a): ERAS-007 in combination with palbociclib","type":"EXPERIMENTAL"},{"description":"ERAS-007 will be orally administered at the recommended dose (as determined from Parts A1a, A2a or A3a) in combination with encorafenib and cetuximab to study participants with BRAFm CRC.","label":"Dose Expan (Parts A1b, A1c, A2b, A2c, A3b, or A3c): ERAS-007 in combo with encorafenib & cetuximab","type":"EXPERIMENTAL"},{"description":"ERAS-007 will be orally administered at the recommended dose (as determined from Parts B1a, B2a, B3a or B4a) in combination with palbociclib to study participants with KRASm or NRASm CRC.","label":"Dose Expansion (Parts B1b, B2b, B3b, and B4b): ERAS-007 in combination with palbociclib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-01-26","type":"ACTUAL"},"conditions":["Metastatic Colorectal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":101,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ERAS-007","otherNames":[],"type":"DRUG"},{"name":"Encorafenib","otherNames":["Braftovi"],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"DRUG"},{"name":"Palbociclib","otherNames":["Ibrance"],"type":"DRUG"}],"last_update":"2026-03-25","lead_sponsor":"Erasca, Inc.","official_title":"A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-08-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose Limiting Toxicities (DLT)","timeFrame":"Study Day 1 up to Day 29"},{"measure":"Maximum Tolerated Dose (MTD)","timeFrame":"Study Day 1 up to Day 29"},{"measure":"Recommended Dose (RD)","timeFrame":"Study Day 1 up to Day 29"},{"measure":"Adverse Events","timeFrame":"Assessed up to 24 months from time of first dose"}],"references":[],"start_date":{"date":"2021-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","url":"https://clinicaltrials.gov/study/NCT05039177"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/herkules-3-nct05039177"}